Moleculin Biotech (MBRX) Competitors $0.55 +0.02 (+3.01%) Closing price 04:00 PM EasternExtended Trading$0.52 -0.03 (-5.65%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MBRX vs. MAAQ, INKT, MRNS, ALLK, OVID, NRSN, DYAI, ENLV, SNYR, and TPSTShould you be buying Moleculin Biotech stock or one of its competitors? The main competitors of Moleculin Biotech include Mana Capital Acquisition (MAAQ), MiNK Therapeutics (INKT), Marinus Pharmaceuticals (MRNS), Allakos (ALLK), Ovid Therapeutics (OVID), NeuroSense Therapeutics (NRSN), Dyadic International (DYAI), Enlivex Therapeutics (ENLV), Synergy CHC (SNYR), and Tempest Therapeutics (TPST). These companies are all part of the "pharmaceutical products" industry. Moleculin Biotech vs. Its Competitors Mana Capital Acquisition MiNK Therapeutics Marinus Pharmaceuticals Allakos Ovid Therapeutics NeuroSense Therapeutics Dyadic International Enlivex Therapeutics Synergy CHC Tempest Therapeutics Mana Capital Acquisition (NASDAQ:MAAQ) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability. Do analysts rate MAAQ or MBRX? Moleculin Biotech has a consensus price target of $4.00, suggesting a potential upside of 627.14%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Moleculin Biotech is more favorable than Mana Capital Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mana Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Moleculin Biotech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is MAAQ or MBRX more profitable? Mana Capital Acquisition's return on equity of 0.00% beat Moleculin Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Mana Capital AcquisitionN/A N/A N/A Moleculin Biotech N/A -278.80%-100.11% Which has higher valuation and earnings, MAAQ or MBRX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMana Capital AcquisitionN/AN/AN/AN/AN/AMoleculin BiotechN/AN/A-$21.76MN/AN/A Do insiders & institutionals hold more shares of MAAQ or MBRX? 68.4% of Mana Capital Acquisition shares are held by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are held by institutional investors. 1.9% of Moleculin Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media prefer MAAQ or MBRX? In the previous week, Moleculin Biotech had 6 more articles in the media than Mana Capital Acquisition. MarketBeat recorded 6 mentions for Moleculin Biotech and 0 mentions for Mana Capital Acquisition. Moleculin Biotech's average media sentiment score of 1.11 beat Mana Capital Acquisition's score of 0.00 indicating that Moleculin Biotech is being referred to more favorably in the news media. Company Overall Sentiment Mana Capital Acquisition Neutral Moleculin Biotech Positive SummaryMoleculin Biotech beats Mana Capital Acquisition on 6 of the 9 factors compared between the two stocks. Get Moleculin Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MBRX vs. The Competition Export to ExcelMetricMoleculin BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.54M$2.99B$5.61B$9.11BDividend YieldN/A2.39%5.24%4.01%P/E RatioN/A7.5819.7619.92Price / SalesN/A292.00430.8999.65Price / CashN/A42.8637.4658.16Price / Book0.317.638.045.49Net Income-$21.76M-$55.05M$3.18B$250.27M7 Day Performance57.17%8.54%3.72%4.78%1 Month Performance-20.22%5.38%3.72%7.20%1 Year Performance-86.11%2.35%29.92%17.27% Moleculin Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MBRXMoleculin Biotech3.2484 of 5 stars$0.55+3.0%$4.00+627.1%-84.2%$7.54MN/A0.0020Positive NewsGap DownMAAQMana Capital AcquisitionN/A$3.79-0.3%N/A+589.0%$30.79MN/A0.001INKTMiNK Therapeutics1.2466 of 5 stars$7.62+5.8%$37.50+392.1%-11.1%$30.40MN/A-3.0230Trending NewsGap UpTrading HaltedMRNSMarinus Pharmaceuticals2.238 of 5 stars$0.55-0.2%$3.92+613.3%-55.4%$30.32M$30.99M-0.22110ALLKAllakos2.9715 of 5 stars$0.33flat$2.00+507.7%N/A$29.74MN/A-0.16190OVIDOvid Therapeutics4.7333 of 5 stars$0.42-3.0%$3.13+649.4%-52.1%$29.72M$570K-1.1960Gap UpHigh Trading VolumeNRSNNeuroSense Therapeutics2.6891 of 5 stars$2.13+1.2%$14.00+558.8%+117.5%$28.98MN/A-3.9310News CoverageAnalyst ForecastDYAIDyadic International2.3428 of 5 stars$0.95+1.5%$6.00+533.6%-27.0%$28.50M$3.49M-4.737Gap DownENLVEnlivex Therapeutics2.9143 of 5 stars$1.19+0.8%$10.00+740.3%-4.3%$28.14MN/A-1.8070SNYRSynergy CHC3.9789 of 5 stars$3.04-7.9%$10.00+228.9%N/A$27.94M$34.83M0.0040Gap UpTPSTTempest Therapeutics2.4506 of 5 stars$7.49+0.7%$30.00+300.5%-73.7%$27.56MN/A-0.4220 Related Companies and Tools Related Companies MAAQ Competitors INKT Competitors MRNS Competitors ALLK Competitors OVID Competitors NRSN Competitors DYAI Competitors ENLV Competitors SNYR Competitors TPST Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MBRX) was last updated on 7/11/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moleculin Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moleculin Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
